Adjuvant Therapy for Melanoma Prolongs RFS

Abstract

The PD-1 inhibitor pembrolizumab may be an effective adjuvant therapy for patients with stage III melanoma. In a clinical trial, patients who received the drug had a 12-month recurrence-free survival rate of 75.4%, compared with 61% for patients who received a placebo.